Cel Sci Believes That Boosting A Patient S Immune System While It Is Still Intact Should Provide The Greatest Possible Impact On Survivalmultikine Is Designed To Help The Immune Systemtargetthe Tumor At A Time When The Immune System Is Still Relatively Intact And Thereby Thought To Be Better Able To Mount An Attack On The Tumorin The Completed Phase 3 Studycel Sci Studied Patients Who Were Newly Diagnosed With Locally Advanced Primary Squamous Cell Carcinoma Of The Head And Neck With The Investigational Product Multikine Administered Firstbefore They Received The Standard Of Carewhich Involved Surgery Followed By Either Radiation Or Chemoradiationthe Phase 3 Study Enrolled 928 Patientsour Approach Is Unique Because Most Other Cancer Immunotherapies Are Administered Only After Conventional Therapies Have Been Tried And Or Failed After Analyzing Data From The Phase 3 Studywe Have Better Defined The Target Population For Multikinewhich Is Locally Advanced Primary Head And Neck Cancer Patients With No Lymph Node Involvement And With Low Pd L1 Tumor Expressionin The Phase 3 Studywe Observed Statistically Significant Survival In This Target Populationshowing That Multikine Cut The Risk Of Death In Half At Five Years Vs Controlmultikineleukocyte Interleukininjectionreceived Orphan Drug Designation From The Fda For Neoadjuvant Therapy In Patients With Squamous Cell Carcinomacancerof The Head And Neck Multikine Is The Trademark We Have Registered For This Investigational Therapyand This Proprietary Name Is Subject To Review By The Fda In Connection With Our Future Anticipated Regulatory Submission For Approval
